It’s not clear what the company means by that. A spokesperson for the US Department of Agriculture, Seth Christensen, said he was not able to confirm whether the agency had corresponded with Haemanthus.

“USDA does regulate vet diagnostics,” including blood testing, Christensen said.

Evans responded in an interview, “When you’re in stealth, you’re trying to be in stealth. They aren’t going to find anything associated with the name Haemanthus.” Evans sent a partially redacted document from the USDA that said, “It does not appear that the proposed product is within the regulatory jurisdiction” of the Centre for Veterinary Biologics, which is a part of the USDA.

Evans, the 33-year-old heir to a California hotel fortune who met Holmes while federal authorities were investigating her, has not publicly discussed the new venture. The documents indicate he has assembled roughly 10 employees. He describes his employment on social media simply as working for a “stealth start-up.”

James Breyer, a well-known venture capitalist and early investor in Facebook, said his team had been asked to put in money and decided against it “for many of the same reasons we passed twice on Theranos”.

“In diagnostics, we’ve long held that the difference between a compelling story and a great company lies in scientific defensibility and clinical utility,” he wrote in an email.

If sequels are de rigueur in the so-called disruptive world of technology, this one is particularly bold. Theranos became one of the world’s most celebrated start-ups last decade and attracted big-time investors (Rupert Murdoch, Larry Ellison) and a board of advisers that included Henry Kissinger.

Holmes, often clad in a black turtleneck that invited comparisons to Apple founder Steve Jobs, was feted on magazine covers and at the White House.

Few knew that Theranos’ technology could not diagnose hundreds of conditions it claimed it could. As was chronicled in The Wall Street Journal, a bestselling book, a podcast, TV series and later criminal proceedings, Theranos was largely using third-party technology to run rudimentary assays — when it did any testing at all. Patients received false diagnoses. The company crumbled before Holmes’ indictment for fraud.

Loading

Holmes, who has always maintained she is innocent, was convicted of fraud in 2022 and sentenced to 11 years in prison. She is incarcerated in a Bryan, Texas, federal prison.

Evans’ idea for Haemanthus traces back at least a year and a half, when he incorporated the company in Delaware, according to public corporate filings. Documents filed in Delaware and Texas show that its offices have been at various addresses in the trendy South Lamar neighbourhood of Austin, Texas, where Evans lives with his and Holmes’ two children.

Haemanthus began by soliciting $US3.5 million ($5.45 million) in funding from friends and family, and this spring began reaching out to other well-to-do backers in Austin and the San Francisco Bay Area for an additional $US15 million, according to the investor materials.

Billionaire Michael Dell’s investment firm turned down the effort, according to two people briefed on the outreach.

The one investor who could be identified in public records is Matthew Parkhurst, a part-owner of a Mediterranean tapas bar in downtown Austin and other investments. Parkhurst did not respond to requests for comment.

Much of the Haemanthus executive team hails from Luminar, a struggling self-driving car company where Evans worked for two years, according to his LinkedIn profile.

Pet healthcare is the first market Evans’ company aims to address. The start-up has thus far received one patent.

According to the company’s marketing materials and patent, the Haemanthus device will use a laser to scan blood, saliva or urine from pets and analyse the samples on a molecular level. In a matter of seconds, the marketing material said, Evans’ machine would be able to identify and qualify biomarkers such as glucose and hormones, and deploy what the company calls deep learning models to detect cancer and infections.

Loading

Haemanthus told investors it had roughly two dozen advisers, including veterinarians and diagnosticians, though it did not name them.

Haemanthus’ materials say the long-term goal is to develop a stamp-size, wearable version of the product for humans. “Based on our experience and partner input,” it says, that will require three years and $US70 million.

The investor presentation makes no mention of Evans’ connection to Holmes.